Pfizer's Ibrance clears first hurdle to early access in U.K.

Pfizer's ($PFE) new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative medicine" tag from the country's Medicines and Healthcare Regulatory Agency. Since scoring a quick FDA approval last February, the breast cancer-fighter--green-lighted for patients with tumors that are estrogen-receptor-positive but HER2-negative--has been tearing it up in the marketplace. In Q3, Ibrance netted $230 million in sales, burying the $195 million analysts expected. Report